The way forward for Ketamine and Mood Disorders In 2019, the FDA and European Fee authorized using an esketamine nasal spready under the brand name identify Spravato to treat melancholy. Nonetheless, as of 2021, ketamine has not been authorized from the FDA to treat despair or other mental health disorders, https://barrettp528ade9.wonderkingwiki.com/user